Project Grant R01HL171174
Award Date
8/5/24
Completion Date
4/30/29
Dollars Obligated
$2.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to identify pathogenic variants and factors influencing variable expressivity of hypertrophic cardiomyopathy (HCM). The $126,306 award, with a period of performance from December 2024 to November 2026, will enable the University of Washington to establish a high-throughput system using human induced pluripotent stem...
This $756,039 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to understand the impact of regulatory genetic variants on the severity of cardiomyopathies caused by haploinsufficiency genes, such as MYBPC3 and DSP. The 5-year project, led by researchers at the University of Michigan, will use human induced pluripotent stem cell cardiomyocytes and mouse models to quantify the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $719,462 to Baylor College of Medicine to develop a high-throughput variant interpretation approach for the MYH7 gene, which is broadly applicable to other cardiomyopathies and genetic diseases. The central hypothesis is that MYH7 variants will lead to gene expression profile changes that can serve as a sensitive marker to predict...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The key products and services to be delivered include: Using high-throughput CARDIO and Perturb-seq assays, the project will analyze the impact of loss of genes associated with heart failure risk through morphological...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,185,454 to Tufts Medical Center to investigate the role of the FHOD3 gene variant in regulating the autophagy pathway and its impact on the development of hypertrophic cardiomyopathy (HCM) and heart failure. The research aims to evaluate the effects of stimulating or inhibiting autophagy in FHOD3 variant mice, as well as assessing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere structure and function, and link these mechanisms to the development of hypertrophic cardiomyopathy (HCM). The $730,764 award to Case Western Reserve University, spanning from June 1, 2025, to March 31, 2029, will utilize a comprehensive...
The federal Project Grant award K08HL179262, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research led by Dr. Joshua Meisner at the University of Michigan to elucidate the mechanical and metabolic pathways underlying MYBPC3-related hypertrophic cardiomyopathy (HCM). The $167,400 award, granted on May 15, 2025, aims to establish mouse and induced pluripotent stem cell models of severe, adolescent-onset...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $667,704 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The award, effective February 1, 2025 through November 30, 2028, will support research to develop chemically inducible split base editors for precise and controllable in vivo genome editing, with a focus on correcting the...
This $135,840 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multi-scale computational and experimental platform to investigate the mechanisms of cardiac contractile dysfunction in common cardiomyopathies. The research aims to establish a framework for understanding how structural perturbations to the myosin motor protein affect its interaction with actin, and to develop small molecule...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $2,044,805 to Case Western Reserve University to advance the understanding of molecular mechanisms underlying genetic cardiac myosin binding protein C (cMyBP-C) cardiomyopathies. The 4-year research project integrates experimental approaches across molecular biology, biophysics, animal physiology, and computer modeling to...